Department of Gastroenterology, Osaka General Hospital of West Japan Railway Company, Osaka, Japan.
Division of Hepatology and Pancreatology, Department of Internal Medicine, Aichi Medical University, Aichi, Japan.
J Gastroenterol Hepatol. 2023 Jun;38(6):896-904. doi: 10.1111/jgh.16144. Epub 2023 Mar 16.
Noninvasive tests (NITs) have prognostic potential, but whether NITs are comparable with liver biopsy is unclear. This study aimed to examine the prognostic accuracy of NITs for liver-related mortality (LRM) and events (LREs) in patients with biopsy-proven nonalcoholic fatty liver disease (NAFLD).
We investigated 1313 patients with NAFLD. Patients were assigned to low-risk, indeterminate-risk, and high-risk groups using conventional cutoff values of each FIB-4 and NAFLD fibrosis score (NFS) and to stage 0-2 and stage 3-4 groups using the fibrosis stage. Survival and Cox regression analyses of the prognostic potential of NITs for LRM/LREs were conducted.
During a median follow-up of 4.5 years, regarding to FIB-4, the incidence rate (/1000 person-years) in the low risk was zero for LRM and 0.5 for LREs. In contrast, the rate in stage 0-2 was 1.3 for LRM and 2.8 for LRE. The adjusted hazard ratios (aHRs) for LREs in the high risk compared with the low risk were 32.85 (P < 0.01). The aHRs in stage 3-4 compared with stage 0-2 were 2.68 (P = 0.02) for LREs and 2.26 (P = 0.582) for LRM. In the same fibrosis stage, the incidence of LRM/LREs was more frequent with a higher risk stratification. The same trend was observed for NFS.
NITs accurately predict LRM and LREs as well as a liver biopsy in Japanese patients with NAFLD. Patients in the low risk may not require close follow-up for at least 5 years. The simple NITs could be an acceptable alternative method to performing a liver biopsy for the prognosis of NAFLD.
非侵入性检查(NIT)具有预测预后的潜力,但它们与肝活检的可比性尚不清楚。本研究旨在探讨 NIT 对经活检证实的非酒精性脂肪性肝病(NAFLD)患者肝相关死亡率(LRM)和事件(LREs)的预测准确性。
我们调查了 1313 名 NAFLD 患者。使用每个 FIB-4 和 NAFLD 纤维化评分(NFS)的常规临界值,将患者分为低危、不确定风险和高危组,并使用纤维化分期将患者分为 0-2 期和 3-4 期组。对 NIT 预测 LRM/LREs 的预后能力进行生存和 Cox 回归分析。
在中位随访 4.5 年期间,对于 FIB-4,低危组 LRM 的发生率(/1000 人年)为零,LREs 为 0.5。相比之下,0-2 期的发生率分别为 LRM 1.3 和 LREs 2.8。与低危相比,高危组 LREs 的调整后风险比(aHR)为 32.85(P<0.01)。与 0-2 期相比,3-4 期的 aHR 分别为 LREs 2.68(P=0.02)和 LRM 2.26(P=0.582)。在相同的纤维化分期中,随着风险分层的增加,LRM/LREs 的发生率更高。NFS 也呈现出相同的趋势。
NIT 可以准确预测日本 NAFLD 患者的 LRM 和 LREs,以及肝活检。至少在 5 年内,低危患者可能不需要密切随访。简单的 NIT 可能是一种可接受的替代方法,用于预测 NAFLD 的预后,而无需进行肝活检。